千金药业(600479) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,000,740,881.98, representing a year-on-year increase of 4.22%[5] - The net profit attributable to shareholders for the same period was CNY 46,198,047.86, up by 5.22% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 21.25% to CNY 43,508,641.61[5] - Basic earnings per share for Q1 2024 were CNY 0.1077, an increase of 5.48% year-on-year[6] - Total operating revenue for Q1 2024 reached ¥1,000,740,881.98, a 4.1% increase from ¥960,198,380.73 in Q1 2023[20] - Net profit for Q1 2024 was ¥61,007,849.98, compared to ¥56,747,393.26 in Q1 2023, representing a 7.9% increase[21] - Total comprehensive income for Q1 2024 was ¥61,007,602.99, compared to ¥56,747,616.03 in Q1 2023, indicating a growth of 7.9%[21] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -170,209,301.10, reflecting a decrease of 12.28%[5] - Cash flow from operating activities showed a net outflow of ¥170,209,301.10 in Q1 2024, an improvement from a net outflow of ¥194,039,475.06 in Q1 2023[23] - The company reported a net cash decrease of ¥198,089,415.83 in Q1 2024, contrasting with a net increase of ¥159,552,755.19 in Q1 2023[24] - The company's cash and cash equivalents decreased to RMB 1,800,315,939.91 from RMB 1,997,900,027.66, representing a decline of approximately 9.8%[16] - The company’s cash and cash equivalents at the end of Q1 2024 stood at ¥1,730,242,722.36, down from ¥1,263,103,574.11 at the end of Q1 2023[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,737,177,415.73, a 1.29% increase from the end of the previous year[6] - As of March 31, 2024, the company's total assets amounted to RMB 4,737,177,415.73, an increase from RMB 4,676,882,466.57 as of December 31, 2023, reflecting a growth of approximately 1.3%[19] - The company's current assets totaled RMB 3,574,769,233.34, up from RMB 3,514,485,567.65, indicating an increase of about 1.7%[17] - Total liabilities stood at RMB 1,662,039,560.63, a marginal increase from RMB 1,650,127,894.00, reflecting a growth of approximately 0.7%[18] - The company's equity attributable to shareholders reached RMB 2,437,368,410.63, up from RMB 2,389,672,141.89, indicating an increase of about 2.0%[18] Research and Development - The company's R&D expenses surged by 153.14%, indicating increased investment in research and development[10] - Research and development expenses surged to ¥60,460,413.73 in Q1 2024, significantly higher than ¥23,884,290.27 in Q1 2023, marking an increase of 152.5%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,061[12] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., held 27.83% of the shares, amounting to 119,381,136 shares[13] Other Financial Metrics - The company's cash flow from financing activities decreased significantly by CNY -169,547.99, primarily due to the payment for repurchased incentive equity[11] - The company's short-term borrowings decreased to RMB 41,945,683.75 from RMB 56,686,470.44, indicating a reduction of about 26.0%[18] - Accounts receivable rose significantly to RMB 384,217,107.49 from RMB 250,400,422.51, marking an increase of around 53.2%[16] - Inventory levels increased slightly to RMB 550,686,832.67 from RMB 534,136,582.86, showing a growth of about 3.1%[16] - The non-current assets remained stable at RMB 1,162,408,182.39, slightly up from RMB 1,162,396,898.92[17] - The company reported a significant increase in other receivables, which rose to RMB 131,323,641.96 from RMB 28,260,309.46, reflecting a growth of approximately 364.5%[16]